|Symbol||Name||Last Price||Change||% Change||Day Low||Day High|
Click to View Charting
Renalytix AI is a developer of artificial intelligence ("AI") decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. The Company was incorporated in March 2018 as a wholly-owned subsidiary of EKF Diagnostics Holdings plc ("EKF"), the AIM-quoted point-of-care diagnostics business. The Company's creation was the first step in EKF's announced strategy to spin-out certain biomarker and AI technology to facilitate its further development and commercialisation. RenalytixAI is currently working in collaboration with world-leading medical institutions to secure development and commercial launch of two artificial intelligence guided products, KidneyIntelX? and KidneyIntelX? APOL1, which the Company intends to submit for FDA review. Subject to funding, the Company is also expecting to develop further products throughout the kidney disease lifecycle, including tools to more accurately assess the type and amount of immunosuppression drugs needed by patients who have undergone kidney transplant surgery (FractalDx). The Company's main country of operation is the United States.
Singer Advisory LLP (together with its associates, "N+1 Singer")